lutetium Lu 177 EB-PSMA-617

{
  "id": "MLC-T-ONC-014915",
  "term": "lutetium Lu 177 EB-PSMA-617",
  "field": "Oncology and biomedicine",
  "definition": "A radioconjugate composed of PSMA-617, a human prostate-specific membrane antigen (PSMA)-targeting ligand, conjugated to the Evans blue (EB) moiety and linked via the macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) to the beta-emitting radioisotope lutetium Lu 177 (177Lu), with potential antineoplastic activity against PSMA-expressing tumor cells. Upon intravenous administration of lutetium Lu 177 EB-PSMA-617, EB-PSMA-617 targets and binds to PSMA-expressing tumor cells. Upon binding, PSMA-expressing tumor cells are destroyed by 177Lu through the specific delivery of beta particle radiation. PSMA, a tumor-associated antigen (TAA) and type II transmembrane protein, is expressed on the membrane of prostatic epithelial cells and overexpressed on prostate tumor cells as well as a variety of other solid tumors. EB-PSMA-617 also binds to serum albumin, which extends its circulation half-life. This may improve tumor uptake and efficacy of the agent.",
  "synonyms": [
    "177Lu-EB-PSMA-617",
    "177 Lu-EB-PSMA-617",
    "177Lu-Evans Blue-modified PSMA-617",
    "lutetium Lu 177-DOTA-EB-PSMA-617",
    "lutetium Lu 177-EB-PSMA-617"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-eb-psma-617/"
}